Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination
| Autor: | Emanuela Oldoni, Michaela Th. Mayrhofer, Andreas Scherer, Jacques Demotes, Laura Maria Garcia Bermejo, Antoni L. Andreu, Anne-Charlotte Fauvel, Anton E. Ussi, Alain J. van Gool, Christine Kubiak, Florence Bietrix, Francesco Florindi |
|---|---|
| Přispěvatelé: | Institute for Molecular Medicine Finland |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Biomedical Research Disease 030204 cardiovascular system & hematology 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center COVID-19 Testing 0302 clinical medicine Pandemic Clinical endpoint Humans Medicine Pandemics Biological Specimen Banks 11832 Microbiology and virology SARS-CoV-2 business.industry COVID-19 biomarkers Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6] Medical research Biobank 3. Good health Viewpoints Clinical trial Identification (information) AcademicSubjects/MED00290 030104 developmental biology Infectious Diseases Risk analysis (engineering) 3121 General medicine internal medicine and other clinical medicine Biomarker (medicine) European Research Infrastructures SARS-CoV-2 pandemic business |
| Zdroj: | Clinical Infectious Diseases Clinical Infectious Diseases, 72, 1838-1842 Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Clinical Infectious Diseases, 72, 10, pp. 1838-1842 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciaa1250 |
| Popis: | An effective response to the coronavirus disease 2019 (COVID-19) pandemic requires a better understanding of the biology of the infection and the identification of validated biomarker profiles that would increase the availability, accuracy, and speed of COVID-19 testing. Here, we describe the strategic objectives and action lines of the European Alliance of Medical Research Infrastructures (AMRI), established to improve the research process and tackle challenges related to diagnostic tests and biomarker development. Recommendations include: the creation of a European taskforce for validation of novel diagnostic products, the definition and promotion of criteria for COVID-19 samples biobanking, the identification and validation of biomarkers as clinical endpoints for clinical trials, and the definition of immune biomarker signatures at different stages of the disease. An effective management of the COVID-19 pandemic is possible only if there is a high level of knowledge and coordination between the public and private sectors within a robust quality framework. Oldoni et al debate relevant issues related to coronavirus disease 2019 testing and biomarker development. European Medical Research Infrastructures call for a high level of knowledge and coordination between public and private sectors, likewise for quality and reproducibility along the research pipeline. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|